Key result
Antithrombin administration was successfully used to manage andexanet alfa-associated heparin resistance.
Case Report
The title suggests that antithrombin administration may be a successful strategy for managing andexanet alfa-associated heparin resistance.
Answers are grounded in this paper and cite their sources.
May warrant antithrombin consideration in andexanet alfa-associated heparin resistance; leaves open need for prospective confirmation.
ANDEXANET ALFA (Ondexxya, Portola Pharmaceuticals, San Francisco, CA) is a modified recombinant inactivated human factor Xa. Although it currently only is approved to reverse the effects of direct factor Xa (FXa) inhibitors, andexanet alfa initially was developed as a reversal agent for direct and indirect FXa inhibitors.1 The agent acts as a decoy FXa molecule that reversibly binds FXa inhibitors and consequently temporarily inhibits the anticoagulant effects. In vitro studies showed a binding affinity for heparin-bound antithrombin and suggested an inhibitory effect against heparin-induced coagulopathy.
No takes yet. Share an insight, caveat, or question.
Apostel et al. (2020) conducted a case report in Andexanet alfa-associated heparin resistance. Antithrombin was evaluated. Antithrombin administration was successfully used to manage andexanet alfa-associated heparin resistance.
Synapse has enriched 10 related papers. Consider them for comparative context: